Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue SUPPL. 3, 2002, Pages

  Press, Natasha ^a,b   Tyndall, Mark W ^a   Wood, Evan ^a   Hogg, Robert S ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Adherence; Antiretroviral therapy; Outcome

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILLNESS BEHAVIOR; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MEASUREMENT; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0037114851     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200212153-00005     Document Type: Conference Paper

References (32)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
2. Cameron DW, Heath-Chiozzi M, Danner S, et al. Prolongation of life and prevention of AIDS complications in a randomized controlled clinical trial of ritonavir in patients with advanced HIV disease. Lancet 1998;351:543-9.
3. Montaner JSG, Reiss P, Cooper D, et al. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-7.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998:338:853-60.
5. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after the initiation of triple-drug antiretroviral regimens. CMAJ 1999;160:659-65.
6. Lucas GM, Chalsson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
8. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360.
9. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999;13:1099-107.
10. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000;23:386-95.
11. DeMasi RA, Graham NM, Tolson JM, et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Adv Ther 2001;18:163-73.
12. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15:2109-17.
13. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
14. Nieuwkerk P, Gisolf E, Sprangers M, et al. Adherence over 48 weeks in an antiretroviral clinical trial: Variable within patients, affected by toxicities and independently predictive of virological response. Antivir Ther 2001;6:97-103.
15. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-21.
16. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-79.
17. Wood E, Hogg R, Yip B, et al. The impact of baseline CD4 T-Cell count and adherence on rates of disease progression among HIV-infected patients initiating triple drug therapy [abstract 465-M]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 24-28, 2002.
18. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-8.
19. Bangsberg DR, Perry S, Charlebois ED, et al. Adherence to HAART predicts progression to AIDS. AIDS 2001;15:1181-3.
20. Knobel H, Carmona A, Guelar A, et al. Adherence in patients treated with HAART: Influence in hospital admissions [abstract MoPeD2556]. Presented at the XIIIth International AIDS Conference, Durban, July 9-14, 2000.
21. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly-active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-8.
22. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002;109:61.
23. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J 2000;19:1148-53.
24. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999;18:682-9.
25. Pradier C, Carrieri P, Bentz L, et al. Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. Int J STD AIDS 2001;12:324-8.
26. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000;14:151-5.
27. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-74.
28. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immun Defic Syndr 2001;27:251-9.
29. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIV-NET 012 randomised trial. Lancet 1999;354:795-802.
30. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
31. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote D'lvoire and Burkino Faso: A double-blind, placebo-controlled multicentre trial. Lancet 1999;353:786-92.
32. Wilson TE, Ickovics JR, Fernandez I, et al. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol 2001;184:1235-40.